COVID-19 Vaccine: Gurgaon-based Premas Biotech enters vaccine race with triple antigen vaccine prototype
Last updated on February 13th, 2023 at 04:40 pm
With the development of the triple antigen vaccine prototype, Gurgaon-based Premas Biotech is the latest entrant in the COVID-19 vaccine development race.
Premas Biotech is however developing a multi sub-unit triple antigen vaccine. This is unlike the other pharma companies across the world who are doing trials for single-protein vaccines.
This vaccine prototype is amongst the first in the world for virus-like particles of SARS- CoV-2.
Dr. Prabuddha Kundu, co-founder and Managing Director of Premas Biotech, said, “The vaccine contains the Spike (S), Envelope (E) and Membrane (M) proteins in simple formats. The idea is to provide a good chance of immunity against COVID-19.”
Researchers have found that there are mutations in the Spike protein component of the SARS – CoV -2 virus. This makes the virus more contingent. The pharma moguls who were developing vaccines using only the Spike protein component of the virus might have reached roadblock due to this reason and threw a spanner in the vaccine maker’s efforts.
The high tendency of the COVID-19 virus to mutate can be well handled by this approach of triple antigen. The researchers say that the idea behind the development of the triple antigen vaccine is to cover all the proteins of the virus and hopefully tackle the present and future mutations in the virus, thus developing a vaccine for prolonged immunity.
Read: Migrant crisis: Opposition led by Congress meet today, political notables choose to stay away
In a press release, Premas Biotech conferred that it has successfully completed the vaccine prototype by “obtaining Transmission electron microscope (TEM) images of the recombinant virus-like particle (VLP) assembled using its D-Crypt platform.”
US-based pharma mogul Ackers Biosciences has acquired the license to develop the Premas Biotech triple antigen vaccine prototype further.
Premas Biotech uses the genetically modified version of the baker’s yeast or Saccharomyces cerevisiae. Based on the proprietary D-Crypt technology that was developed in India in the past decade, this research methodology recombinantly produces the 3 antigens in a single host body. This further makes this vaccine candidate safe potentially and is also easy to manufacture at a large scale more cost-effectively.
These features of this vaccine candidate are in favor to help millions of people affected globally.
To read more Coronavirus news: https://indiaobservers.com/category/coronavirus/